Loading clinical trials...
Loading clinical trials...
Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Conditions
Interventions
CD19 t-haNK- IV Administration
Locations
2
South Africa
Dr. Jackie Thomson Inc
Johannesburg, South Africa
Albert Cellular Therapy
Pretoria, South Africa
Start Date
November 11, 2025
Primary Completion Date
May 25, 2027
Completion Date
May 25, 2028
Last Updated
March 16, 2026
Lead Sponsor
ImmunityBio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions